Inflammatory bowel disease (IBD) results from a dysregulated interaction between the microbiota and a genetically susceptible host. Genetic studies have linked TNFSF15 polymorphisms and its protein TNF-like ligand 1A (TL1A) with IBD, but the functional role of TL1A is not known. Here, we found that adherent IBD-associated microbiota induced TL1A release from CX3CR1 + mononuclear phagocytes (MNPs). Using cell-specific genetic deletion models, we identified an essential role for CX3CR1 + MNPderived TL1A in driving group 3 innate lymphoid cell (ILC3) production of interleukin-22 and mucosal healing during acute colitis. In contrast to this protective role in acute colitis, TL1A-dependent expression of co-stimulatory molecule OX40L in MHCII + ILC3s during colitis led to co-stimulation of antigen-specific T cells that was required for chronic T cell colitis. These results identify a role for ILC3s in activating intestinal T cells and reveal a central role for TL1A in promoting ILC3 barrier immunity during colitis.
In Brief
Inflammatory bowel disease (IBD) results from a dysregulated interaction between the microbiota and a genetically susceptible host. Castellanos et al. show a protective role for microbial induction of the IBD-linked protein TL1A in promoting ILC3 barrier immunity and uncover a pathogenic role for TL1A-induced expression of OX40L on ILC3s in driving chronic T cell colitis.
SUMMARY
Inflammatory bowel disease (IBD) results from a dysregulated interaction between the microbiota and a genetically susceptible host. Genetic studies have linked TNFSF15 polymorphisms and its protein TNF-like ligand 1A (TL1A) with IBD, but the functional role of TL1A is not known. Here, we found that adherent IBD-associated microbiota induced TL1A release from CX3CR1 + mononuclear phagocytes (MNPs). Using cell-specific genetic deletion models, we identified an essential role for CX3CR1 + MNPderived TL1A in driving group 3 innate lymphoid cell (ILC3) production of interleukin-22 and mucosal healing during acute colitis. In contrast to this protective role in acute colitis, TL1A-dependent expression of co-stimulatory molecule OX40L in MHCII + ILC3s during colitis led to co-stimulation of antigen-specific T cells that was required for chronic T cell colitis. These results identify a role for ILC3s in activating intestinal T cells and reveal a central role for TL1A in promoting ILC3 barrier immunity during colitis.
INTRODUCTION
Inflammatory bowel disease (IBD) affects over 4 million people worldwide, causing significant morbidity among patients (Kaplan, 2015) . IBD pathogenesis is thought to be multifactorial, with both intestinal dysbiosis and genetic components underlying disease pathogenesis. Characteristic alterations in the IBD-associated microbiome exist, with marked contraction of intestinal microbial diversity a hallmark of IBD (Gevers et al., 2014) . Genetic studies have identified over 200 genes linked with IBD susceptibility (McGovern et al., 2015) , but our functional understanding of how these genes contribute to intestinal homeostasis and IBD pathophysiology is incomplete, limiting the potential for diagnostic and therapeutic intervention.
Genome-wide association studies (GWAS) in IBD have revealed strong associations of genetic variants in TNFSF15 with Crohn's disease, highlighting a central role for its protein, TNF-like ligand 1A (TL1A), in mucosal immunity (Siakavellas and Bamias, 2015) . Variants in TNFSF15 have been linked to the pathogenesis of several autoimmune diseases-including psoriasis, rheumatoid arthritis, and multiple sclerosis-implicating a broader role for TL1A in human inflammatory diseases. In IBD, TNFSF15 variants confer higher risk for more aggressive, penetrating, fibrostenotic, and perianal disease complications (Tung et al., 2014; Yang et al., 2014) , but the mechanistic impact of TL1A remains controversial. While early studies showed a pathogenic role for TL1A in driving inflammatory T cell responses (Prehn et al., 2004; Zheng et al., 2013) , more recent reports in acute colitis models revealed a protective role for TL1A (Jia et al., 2016) . Genetic models are needed to understand the cellular mechanisms and potential therapeutic targetability of this IBD-linked pathway in intestinal inflammation.
Group 3 innate lymphoid cells (ILC3s) are an emerging class of innate lymphocytes that play a critical role in regulating mucosal homeostasis. In response to the cytokines IL-23 and IL-1b, ILC3s produce robust amounts of IL-22 and play an important role in maintaining intestinal barrier integrity and promoting mucosal healing-a major clinical endpoint in IBD (Longman et al., 2014) . Co-localization of ILC3s with CX3CR1 + mononuclear phagocytes (MNPs) in the lamina propria enables rapid regulation of ILC3 effector cytokines to reinforce barrier immunity and mucosal healing (Satoh-Takayama et al., 2014) . Both mouse and human ILC3s express Death Receptor 3 (DR3), the monogamous receptor for TL1A, on its surface, with TL1A stimulation promoting ILC3 proliferation (Ahn et al., 2015) and cytokine production in vitro (Longman et al., 2014) ; however, the role for TL1A in regulating ILC3 function in intestinal homeostasis, and its potential contribution to IBD pathophysiology, remains unknown. Here, we generated mouse models with selective deletion of TL1A and its receptor DR3 to evaluate the role of this critical IBD-linked genetic pathway in regulating mucosal immunity. Our data revealed a central role for CX3CR1 + MNP-derived TL1A, which is induced by adherent IBD-associated microbiota, in regulating ILC3 production of IL-22 and mucosal healing in acute colitis. In addition to regulating cytokine production, TL1A induced OX40 ligand (OX40L) expression on colonic ILC3 in mouse and human colitis. OX40L expression on MHCII + ILC3s supported antigen-specific T proliferation in vitro and pathogenic T helper 1 (Th1) cell expansion in chronic colitis models. Our findings reveal a central role for IBD-linked TL1A in regulating ILC3 barrier immunity and uncover a mechanistic role for TL1A-induced expression of the co-stimulatory molecule OX40L on MHCII + ILC3s in regulating colonic T cells.
RESULTS
Mononuclear Phagocyte TL1A Promotes Barrier Protection during Acute Colitis CX 3 CR1 + MNPs play a central role in coordinating the mucosal immune response during colitis (Kim et al., 2018; Longman et al., 2014; Panea et al., 2015; Satoh-Takayama et al., 2014) . Recent studies have reported increased TL1A protein in the colonic tissue of both mice and humans during active colitis (Bamias et al., 2013) (Zheng et al., 2013) . To evaluate the cellular source of TL1A in the human intestine, we performed TL1A staining of lamina propria mononuclear cells (LPMCs). TL1A expression was significantly higher on CD14 + HLA-DR hi intestinal MNPs compared to lymphocytes ( Figure 1A ). To evaluate the impact of colitis on MNP expression of TL1A, we performed flow cytometry on LPMCs from endoscopic biopsies from healthy controls (N = 8) or individuals with ileocolonic Crohn's disease (CD, inactive N = 3, active N = 8) (Figures 1B and S1A) . MNPs from CD patients with active inflammation showed significantly higher surface expression of TL1A ( Figure 1B ). Consistent with these data from human CD, selective depletion of CX3CR1 + MNP using mice harboring a diphtheria toxin receptor (DTR) insertion into the Cx3cr1 locus (Cx3cr1 DTR ) (Longman et al., 2014) following diphtheria toxin injection significantly reduced TL1A expression in the intestinal lamina propria ( Figure 1C ). These data demonstrate that CX3CR1 + MNPs are a primary source of intestinal TL1A, which is significantly upregulated during active Crohn's disease.
To evaluate the potential physiological role for MNP-derived TL1A in colitis, we generated mice with a conditional deletion of Tnfsf15 (Tnfsf15 flox/flox ) induced by Itgax-cre to specifically delete TL1A in cells expressing CD11c (Tnfsf15 flox/flox Itgaxcre, subsequently referred to as TL1A DCD11c ). TL1A mRNA expression in lamina propria CD11c + cells was used to confirm deletion ( Figure S1B ). TL1A DCD11c mice exposed ad libitum to 2% dextran sodium sulfate (DSS) for 7 days lost significantly more weight than their littermate controls (Figure 1D Figure S1C ). To examine a role for CX3CR1 + MNP-derived TL1A in vivo, TL1A DCX3CR1 and their littermate controls were exposed to 2% DSS for 7 days. TL1A DCX3CR1 mice lost significantly more weight than their littermate controls and had increased histopathological damage ( Figures 1E and 1F) .
Previous studies have demonstrated that TL1A can affect both T cell and innate lymphoid cell function (Richard et al., 2015) . To evaluate the impact of MNP-specific TL1A deletion in regulating lymphocyte effector function during colitis, flow cytometry was performed on LPMCs. Although no differences were seen in T cell subsets or cytokine production ( Figures 1G and S1D ), there was a statistically significant reduction in IL-22 production by ILC3s in TL1A-deficient mice ( Figures 1H and S1E ). There were no differences in total ILC3 numbers in the colon ( Figure S1F ) or in ILC3 production of IL-17 or IFN-g. These models illustrate a central role for MNP-derived TL1A in regulating the innate response to acute colitis. to sample luminal microbes and respond to microbial products through Toll-like receptor signaling (Diehl et al., 2013) . Given the ability of bacterial signals to induce TL1A mRNA in human antigen-presenting cells (Shih et al., 2009) , we evaluated the effect of MyD88-deficiency on TL1A expression in gut MNPs.
MNPs from mice with MyD88-deletion showed a significant reduction in MNP TL1A expression ( Figure 2A ). Although CX3CR1 promotes direct microbial sampling via transepithelial dendrites (Niess et al., 2005) , CX3CR1-deletion did not affect TL1A expression. To test the role for microbial regulation of TL1A in vivo, we compared TL1A expression in germ-free mice and specific pathogen free (SPF) mice. Flow cytometric analysis of TL1A expression in CD11c
+ MNPs showed that germ-free mice had a significant reduction in intestinal TL1A protein expression compared to SPF mice (Figure 2B ). Previous studies have reported that microbial adherence to the intestinal epithelial surface may play a critical role in regulating immune responses in the lamina propria. Segmented filamentous bacteria (SFB), for example, adheres tightly to the ileal mucosa and induces Th17 and ILC3 effector function (Ivanov et al., 2009; Sano et al., 2015) . Given the importance of CX3CR1 + MNP in regulating Th17 and ILC3 effector functions (Longman et al., 2014; Panea et al., 2015) , we sought to examine the role for SFB in TL1A regulation. Lamina propria MNPs from germ-free and gnotobiotic mice colonized with SFB were analyzed for TL1A expression ( Figure 2C ). SFB mono-colonized mice had significantly higher intestinal TL1A mRNA compared to germ-free mice. To further test whether this induction of TL1A was selective for adherent bacteria, we used Adherent-invasive E. coli (AIEC) strain 2A and a non-adherent E. coli control strain T75 derived from patients with Crohn's disease (Viladomiu et al., 2017) . At 5 days following colonization, AIEC strain 2A, but not T75, induced TL1A mRNA in the colonic lamina propria ( Figure 2C ). To evaluate the role for microbial regulation of TL1A in SPF mice, we assessed TL1A protein expression using antibiotic-treated Cx3cr1 GFP/WT mice. Flow cytometric analysis of TL1A protein in CX3CR1 + MNPs from antibiotic-treated mice showed a significant reduction in intestinal TL1A compared to SPF mice ( Figure 2D ). The reduction in MNP expression of TL1A protein induced by antibiotics could be restored by colonization with AIEC 2A ( Figure 2E ). Previous studies have reported that CX3CR1 + MNP increase cytokine production during colitis (Zigmond et al., 2012) . To test whether colitis altered CX3CR1 + MNP TL1A, mice were exposed to DSS and TL1A mRNA levels were evaluated in sort-purified CX3CR1 + MNPs.
Barrier disruption with DSS increased TL1A mRNA expression in SPF mice, which was further enhanced after AIEC 2A colonization ( Figure 2E ). Collectively, these data suggest that mucosal-associated microbiota induce MNP TL1A and enhance its production during colitis. We have previously shown that AIEC can also induce IL-22 production by ILC3s in gnotobiotic mice, leading to reduced mortality in acute DSS colitis (Viladomiu et al., 2017) . To test the role for TL1A in AIEC induction of ILC3 IL-22, we colonized antibiotic pre-treated mice with AIEC. Similar to our findings in the DSS-induced acute colitis model, TL1A
DCD11c mice colonized with AIEC showed reduced production of IL-22 compared to littermate controls ( Figure 2F ). To test whether the protective effects of AIEC are dependent on MNP-derived TL1A, TL1A
DCD11c and littermate control mice were pre-treated with broad-spectrum antibiotics and then colonized with AIEC strain 2A prior to DSS exposure. Colonization with AIEC was sufficient to rescue the more severe weight loss and reduced survival following treatment with antibiotics, and this rescue required MNP-derived TL1A ( Figure 2G ). Collectively, these findings reveal a protective link between IBDassociated adherent microbiota and MNP-derived TL1A during acute colitis.
ILC3-Specific DR3 Deficiency Impairs IL-22 Production and Exacerbates Colitis
To evaluate the impact of endogenous TL1A in vivo using experimental colitis models, mice deficient for DR3 (Tnfrsf25 À/À ) were exposed ad libitum to 2% DSS. Similar to recent results (Jia et al., 2016) , DSS induced more severe acute colitis in mice deficient for DR3, as evidenced by increased weight loss with a protracted recovery ( Figure 3A ) and reduced survival ( Figure 3B ). Similar to the TL1A-deficient mice, analysis of CD4 + T cells in the lamina propria did not reveal significant differences in CD4 Although overexpression of TL1A can alter ILC2 function (Meylan et al., 2014) , we observed no effect of DR3 deletion on IL-13 production by ILC2 cells during acute colitis ( Figure S2C ). In contrast, Lin À RORgt + ILC3s from the lamina propria showed a significant decrease in IL-22 ( Figure 3C ). To evaluate the functional significance of reduced IL-22 production by ILC3 during colitis, we injected DR3-deficient mice with recombinant IL-22 following exposure to DSS ( Figure 3D ). Treatment with rIL-22 rescued the reduced survival of DR3-deficient mice, suggesting a critical role for ILC3-derived IL-22 in mediating DR3-dependent mucosal healing.
Other cell types, including CD4 + T cells, can significantly contribute to IL-22 production (Basu et al., 2012 ). Transcriptional and flow cytometric analysis revealed that DR3 DILC3 mice lacked DR3 expression on ILC3, but not on ILC2, confirming cell type-specific DR3 deletion ( Figure S3A ). Absence of DR3 did not change the total number or frequency of ILC3 subsets in the small or large intestines ( Figure S3B ).
To evaluate a role for ILC3-intrinsic DR3 in experimental colitis, we exposed DR3 DILC3 mice and their littermate controls to ad libitum 2% DSS. Phenocopying DR3-deficiency, DR3 DILC3 mice lost significantly more weight ( Figure 3E ) and had more severe colitis histopathology ( Figure 3F ) than their littermate controls. Flow cytometry analysis revealed lower production of IL-22 by ILC3s from DR3 DILC3 mice compared to littermate controls (Figure 3G ). Similar to DR3-deficient animals, treatment with rIL-22 rescued the reduced survival of DR3 DILC3 ( Figure 3E ). IL-22 is critical for inducing intestinal epithelial cell production of antimicrobial peptides (Kinnebrew et al., 2012) and the acute phase reactant serum amyloid A (Sano et al., 2015) . Reduced expression of both Reg3g and Saa1 in intestinal epithelial cells from DR3 DILC3 mice ( Figure 3H ) demonstrates the functional impact of reduced IL-22 in ILC3-specific deletion of DR3 during colitis.
To test the role for DR3 in infectious colitis, we used the Citrobacter rodentium colitis model, which is dependent on ILC3s during the acute response (Sonnenberg et al., 2011) . Similar to the response in DSS colitis, DR3 DILC3 mice lost significantly more weight and had reduced survival compared to littermate controls ( Figure 3I ). Collectively, these experiments demonstrate a key role for cell-intrinsic DR3 in regulating ILC3 production of IL-22 and protection from acute experimental colitis.
TL1A Synergizes with IL-23 via p38 MAPK to Mediate Protection in Acute Colitis
To investigate the mechanism for TL1A regulation of ILC3-derived IL-22, we sorted Lin À CD127 + IL-23R GFP ILC3s from the small intestinal lamina propria ( Figure S4A ) and stimulated ex vivo with either recombinant TL1A, IL-23, or TL1A+IL-23. Although both IL-23 and TL1A induce IL-22 transcription ( Figure 4A ), concomitant stimulation with both IL-23 and TL1A induced a robust synergistic IL-22 response ( Figure 4A ). We confirmed TL1A synergy with IL-23 was DR3-dependent by sorting ILC3s from DR3-deficient mice as well as heterozygous and WT littermate controls ( Figure 4B Figure S4B ). Additionally, ex vivo TL1A stimulation of sorted intestinal ILC3 revealed synergistic induction of IL-22 protein in all subsets ( Figure 4C ). Conventional signaling downstream of DR3 can occur through mitogen-activated protein kinase (MAPK) or NF-kB pathways (Bamias et al., 2013) . To evaluate the role for these signaling pathways in mediating TL1A and IL-23 synergistic induction of IL-22, we profiled protein phosphorylation by flow cytometry. Our results revealed significant phosphorylation of IkBa and p38-MAPK but not ERK following TL1A stimulation of sorted intestinal ILC3s ( Figure 4D ). To test the dependence on MAPK or NF-kB signaling, we sorted ILC3s and pre-treated with soluble inhibitors prior to ex vivo TL1A stimulation. Although the NF-kB inhibitor NBD did not affect IL-22 production, pre-treatment with TAK1 or p38 MAPK inhibitors (5Z-7-Oxozeaenol and SB203580, respectively) completely blocked TL1A and IL-23 synergistic induction of IL-22 ( Figure 4E ). No significant increase in STAT3 phosphorylation was detected in ILC3s stimulated with TL1A and IL-23 compared to IL-23 stimulation alone (Figure S4C) , and no transcriptional increase in Rorc, Ahr, HIF1a, or Stat3 was detected in ILC3s stimulated with TL1A to account for the increase in IL-22 ( Figure S4D ). In monocyte-derived macrophages, TL1A synergy with muramyl dipeptide requires autocrine IL-1b to induce inflammatory cytokines (Hedl and Abraham, 2014) . However, in contrast to this pathway used in macrophages, IL-1R on ILC3 was dispensable for TL1A and IL-23 synergistic induction of IL-22 ( Figure 4F ).
To evaluate a physiologic role for IL-23 and TL1A synergy in vivo, we generated mice with both DR3-and IL23R-deficiency (Tnfrsf25
Il23r
GFP/GFP ). Mice with both DR3 and IL23R deficiency showed reduced survival following acute DSS-induced colitis compared to mice with a single deficiency of DR3 or IL23R ( Figure 4G ). Collectively, these data reveal the direct synergy of these IBD-linked pathways in regulating ILC3 production of effector cytokines and protection from acute colitis.
TL1A Induces OX40L-Dependent Co-stimulation of CD4 + T Cells by MHCII + ILC3 In contrast to our findings for an essential role for TL1A and DR3 in protection from acute colitis, previous studies have suggested a pathogenic role for TL1A overexpression in IBD (Zheng et al., 2013) . To identify potential genes and pathways regulated by TL1A that may account for the pathogenic effects of DR3 in ILC3s during chronic colitis, we performed RNA-seq of TL1A-stimulated intestinal ILC3s. ILC3s were sort-purified from Il23r GFP/WT mice and stimulated for 18 hours with or without recombinant TL1A. In addition to induction of Csf2 and Il22, RNA-seq analysis revealed significant induction of the co-stimulatory molecule OX40L following TL1A stimulation ( Figure 5A ), which was confirmed by quantitative PCR of its gene Tnfsf4 (Figure 5B) . Flow cytometric analysis showed induction of surface expression of OX40L in all ILC3 subsets ( Figure 5C ). Previous studies have shown that MHCII + ILC3s lacking surface expression of classical co-stimulatory molecules negatively regulate T cell responses to commensal bacteria (Hepworth et al., 2013) . Therefore, to test whether TL1A-induced expression of OX40L could promote antigen-specific T cell responses, MHCII Figure S4 . Figure S5C ). Sorted intestinal ILC3s from mice without OX40L failed to support OT-II T cell proliferation following TL1A stimulation in vitro ( Figures 5H and S5D) . Finally, to determine whether OX40L was functioning as a costimulatory signal or acting independently of MHCII, we sorted ILC3s from mice with MHCII-deficient ILC3s (H2-Ab1 
ILC3 Expression of OX40L in Colitis Regulates Pathogenic T Cells
To evaluate ILC3 expression of OX40L in vivo during colitis, we performed flow cytometry on lamina propria ILC3s at steady state and following DSS-induced colitis. Although low OX40L was seen on ILC3s at steady state, colitis induced robust surface expression of OX40L protein ( Figure 6A ). Expression of OX40L was significantly reduced on the MHCII + ILC3s from DR3-deficient mice compared to littermate controls, revealing a key role for TL1A in ILC3 expression of OX40L in vivo ( Figure 6B ). To determine whether ILC3s express OX40L during inflammatory bowel disease (IBD), we profiled ILC3s from human intestinal biopsy samples ( Figures  6C and S6 In contrast to littermate controls, which showed a failure to gain weight and intestinal inflammatory infiltrates consistent with T cell colitis, OX40L-deficient mice continued to gain weight and showed no significant intestinal inflammation ( Figures 7C and 7D ). Colonic CD4 + T cell production of IFN-g and T-BET expression was significantly reduced in OX40L-deficient animals compared to controls ( Figures 7E and 7F ). Given the role for TL1A signaling in regulating ILC3 expression of OX40L, we next tested the impact of DR3-deletion in the T cell transfer colitis model. Weight loss and reduced survival consistent with chronic T cell-mediated colitis developed within 4 weeks in the RAG2 À/À littermate controls, but similar to the OX40L-deficient mice, ILC3-specific deletion of DR3 protected mice from T cell transfer colitis ( Figure 7G ). No differences were observed in the microbiome composition of OX40L-or DR3-deficient mice compared to littermate controls ( Figures S7C and S7D) . Analysis of colonic tissue in these mice revealed decreased histopathologic damage ( Figure 7H ) and a significant reduction in T-BET + CD4 + T cells ( Figure 7I ) in the DR3 DILC3 mice compared to littermate controls. Thus, in contrast to the protective role for TL1A in acute colitis, these data reveal a pro-inflammatory role for ILC3-intrinsic DR3 in chronic T cell colitis.
DISCUSSION
Our data highlight the role for the IBD-linked gene TNFSF15 and its protein TL1A as a central regulator of ILC3 function linking innate and adaptive barrier immunity. Previous reports on the role for TL1A in inflammatory colitis offered contradicting results, with TL1A promoting protection in acute colitis (Jia et al., 2016 ) and exacerbating T cell-dependent inflammation in chronic colitis (Zheng et al., 2013) . Using cell-specific genetic deletion models, our results now help to reconcile these findings, revealing a central role for ILC3 in mediating protection in acute colitis, but promoting DR3-dependent pathogenic T cell responses in chronic disease. These findings highlight the protective role for TL1A in promoting mucosal healing during IBD (Bamias et al., 2003; Prehn et al., 2004) . In synergy with IL-23, TL1A can act as a rheostat to regulate ILC3 effector functions. Our results show that TL1A synergy with IL-23 in ILC3s requires p38 MAPK, but does not induce significant change in key transcription factors (Rorc, Ahr, Hif1a) or STAT3 phosphorylation. The direct and indirect mechanistic targets of TL1A regulation of IL-22 in ILC3s still need to be defined. On a population level, genetic variants promoting this TL1A-dependent mucosal healing response may confer protection against infectious pathogens; however, sustained induction of TL1A, in patients with additional genetic susceptibility or environmental exposure, may support pathogenic T cell expansion (Zheng et al., 2013) or effector ILCs during chronic inflammation.
Our results support a key role for IBD-associated adherent bacteria in regulating MNPs as the main producers of intestinal TL1A. As sentinels of barrier immunity, MNPs integrate microbial signals and activate both innate and adaptive effector immunity. By producing IL-23 and IL-1b, as well as CXCL16, MNPs are positioned functionally and spatially to rapidly coordinate ILC3 effector cytokine production (Longman et al., 2014; Satoh-Takayama et al., 2014) . Adherent microbiota, including SFB and Adherent-invasive E. coli, induce TL1A consistent with their ability to potently induce ILC3 production of IL-22 (Sano et al., 2015; Viladomiu et al., 2017) . These findings offer a mechanism by which Crohn's disease-associated microbiota can act acutely to promote barrier immunity in wild-type hosts. The adherence and metabolic characteristics of the intestinal microbiota may offer a novel approach for regulating TL1A effects in the mucosa.
The discovery of antigen processing and presentation by intestinal ILC3 highlights a central role for these cells in linking innate and adaptive immunity (Hepworth et al., 2013) . Although splenic ILC3s can upregulate conventional co-stimulatory molecules CD80 and CD86 following IL-1b stimulation (von Burg et al., 2014) , the absence of these co-stimulatory molecules following stimulation on intestinal ILC3s lead to a model in which they limit bacteria-specific inflammatory T cell responses in the gut (Hepworth et al., 2015) . Our data demonstrate expression of OX40L by ILC3s after TL1A stimulation in mouse colitis models and human IBD. Expression of OX40L by ILC3s plays a critical role in regulating gut antigen-specific and effector T cell responses. Although the total number of intestinal ILC3s are limited, functional and spatial organization of these cells facilitate efficient regulation of immunity in the tissue (Satoh-Takayama et al., 2014) . These data, therefore, extend the model by which MHCII + ILC3s may regulate the intestinal T cell response. In IBD patients with genetic susceptibility or animal models of T cell transfer colitis, ILC3 co-stimulation can support pathogenic inflammatory T cell activation. Under homeostatic conditions, this model may extend to other OX40L-dependent regulatory responses (Griseri et al., 2010) . Recent studies have demonstrated significant heterogeneity in ILC3 populations, including MHCII + and MHCII À subsets (Bjö rklund et al., 2016; Gury-BenAri et al., 2016; Lim et al., 2017) . While our data show an essential role for ILC3-specific OX40L in mediating TL1A-dependent T cell responses, further studies are needed to define intrinsic features of MHCII + or MHCII -ILC3 that contribute to their role in tissue specific T cell regulation. These studies reveal a central role for TL1A in directing ILC3-dependent mucosal immunity. We now propose a model in which MNP-derived TL1A stimulation of intestinal ILC3 serves as a critical component linking innate and adaptive barrier immunity in colitis. During acute colitis, TL1A synergy with IL-23 promotes mucosal healing, but sustained intestinal damage leads to the upregulation of OX40L on ILC3 and co-stimulation of inflammatory intestinal T cells. Our data from IBD patients reveal a conserved TL1A-OX40L pathway in ILC3 with the potential to guide diagnostic and therapeutic approaches for IBD.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: À/À, Cx3cr1-GFP, Cx3cr1-CreER mice were purchased from The Jackson Laboratory. All mouse models were on C57BL/6 background. CX 3 CR1-DTR mice (Longman et al., 2014) were previously described. Il23r GFP mice were obtained from M. Oukka (Awasthi et al., 2009) . Myd88 À/À were obtained from J. Blander. MHCII DILC3 mice were obtained from G. Sonnenberg (Hepworth et al., 2015) . Tnfsf4 flox were provided by T. Vyse and M. Botto (Cortini et al., 2017) . Tnfrsf25 À/À mice were obtained from Cancer Research UK (Wang et al., 2001) . Generation of Tnfrsf25 flox/flox mice is previously described (Shih et al., 2014) . Tnfsf15 flox/flox mice were generated at Cedars-Sinai by D. Shih and S. Targan. Tnfsf15 endogenous locus containing 4.5 bp upstream and 3.4 bp downstream of exon 1 were generated by PCR amplification using proprietary C57BL/6J library developed at genOway. Subsequently, two loxP sites were inserted flanking exon 1. Positive selection neomycin gene flanked by FRT sites was inserted to the intron after exons 1 to generate the targeting vector. Every step of the cloning process was validated through restriction enzyme analysis and sequencing. The Tl1a gene targeting construct was linearized and electroporated into embryonic stem (ES) cells with C57BL/6J background. Homologous recombinants were selected by G418 and confirmed by PCR and Southern blot analysis. ES clones with correct 5 0 and 3 0 recombination were microinjected into C57BL/6J blastocysts and introduced into pseudopregnant C57BL/6J mice. Male chimeric offspring were bred to obtain germline mutant mice, which were then bred to flpe delete mouse strain to remove the neomycin cassette and were confirmed by Southern blot. For CX 3 CR1 + MNP depletion studies using 
DILC3
, 5ug of rIL-22 was injected i.v. on days 4 and 6. All experiments were performed with 6-8 week old littermates. Both male and female mice were used with random and equal assignment of same sex to each experimental group. All vertebrate work was approved by the IACUC at Weill Cornell Medicine.
Human IBD Subjects Endoscopic biopsies were obtained under an Institutional Review Board-approved protocol (1103011578) and informed consent was obtained at Weill Cornell Medicine (WCM) including patients > 18 years of age. Active inflammation was defined by an endoscopic score of > 2 and inactive disease was defined by an endoscopic score of 0. The age and gender of subjects included are as follows: 38, 53, 55, 71, 72, 79 Preparation of LPMC Mouse intestines or human endoscopic biopsies were washed in PBS and 1 mM DTT with 30 mM EDTA, and then digested in collagenase 8 (Sigma-Aldrich) and DNase-containing media with 10% fetal bovine serum. Digested material was passed through a cell strainer and separated on a discontinuous 40%/80% Percoll gradient. LPMCs were cultured ex vivo in the presence of GolgiPlug (BD) for 4 h or stimulated with phorbol myristate acetate (PMA; 20 ng/ml) and ionomycin (1 mg/ml) or IL-23 (40 ng/ml; eBioscience) in the presence of GolgiPlug (BD) for 4 h before staining.
Intestinal ILC Cultures
Lineage -KLRG1 -IL23R-GFP mouse ILC3 were sorted from LPMCs and resuspended in RPMI (10% FBS) tissue culture media for stimulation directly ex vivo. Mouse ILCs were stimulated with mouse recombinant IL-23 (eBioscience; 40 ng/ml), IL-1 (eBioscience; 10 ng/ml), or TL1A (R&D Systems; 200 ng/ml), as indicated. After 18 h, supernatants were harvested for IL-22 or GM-CSF ELISA (eBioscience) and Golgi Plug (BD) was added to cells for 4 h for subsequent intracellular cytokine staining.
Co-culture Assays Sort-purified ILC3 (2x10 4 ) and MNP (1x10 4 ) populations were co-cultured in a 96-well round-bottom plate in tissue culture media. Cultures were incubated at 37 C for 18h. Supernatants were harvested for ELISA and remaining cells were incubated with Golgi Plug (BD) for 4 hours and subsequently analyzed by flow cytometry. For antigen-specific T cell proliferation assays, 2x10 5 sort-purified, CFSE-labeled naive CD4 + T cells from OTII transgenic mice were co-cultured with either 2.5x10 4 sort-purified ILC3 from IL23R GFP/wt mice or 2x10 4 MHCII + CD11c + CD11b + MNPs, with 20ug/mL OVA peptide (OVA 323-339; InvivoGen) and 200ng/mL rTL1A, as indicated, in a 96-well flat bottom plate. For co-stimulatory blocking assays, ILC3/Tcell co-cultures were blocked with 20ug/mL anti-mouse ICOSL antibody (LEAF purified anti-mouse CD275; BioLegend) or 15ug/mL anti-mouse OX40L antibody (Biotin anti-mouse CD252; BioLegend).
Colitis Models
To induce chemical colitis in mice, 2% DSS (w/v) (M.W. 40,000-50,000; Affymetrix) was added to sterile drinking water and administered ad libitum for 7 days. After 7 days, DSS was replaced with normal drinking water. To induce infectious colitis, mice were orally gavaged with log phase growth Citrobacter rodentium DBS100 (ATCC 51459; American Type Culture Collection) at 1x10 10 in PBS.
For T cell transfer colitis, 5x10 5 CD4 + CD45RB high CD25 -CD62L -T cells were transferred into DR3 DILC3 or DR3 flox/flox mice. For all colitis experiments, mice were monitored daily (DSS) or weekly (T cell transfer) for weight loss, rectal bleeding, diarrhea and survival throughout the experiments. For in vivo experiments using AIEC 2A, mice were pre-treated for 21 days with a broad-spectrum antibiotic cocktail of ampicillin (1g/L), neomycin (0.5g/L), metronidazole (0.5g/L) and vancomycin (0.5g/L) in their drinking water. Mice were then orally gavaged with 2x10 9 of AIEC 2A before colitis induction with 2% DSS in their drinking water. For antigen-specific 16S rRNA Gene Sequencing and Analyses 16S rRNA gene sequencing methods were adapted from the methods developed for the Earth Microbiome Project (Caporaso et al., 2011) . Briefly, bacterial genomic DNA was extracted using the Maxwell RSC (Promega). The 16S rDNA V4 and V5 regions were amplified by PCR and sequenced in the MiSeq platform (Illumina) using the 2x250 bp paired-end protocol (Caporaso et al., 2012) . The read pairs were demultiplexed based on the unique molecular barcodes, and reads were merged using USEARCH 10.0.240 (Edgar, 2010) . Taxonomic labeling of OUT representative sequences was carried out with a confidence threshold of 0.8, using the Ribosomal Database Project training set (version 16) (Cole et al., 2014) . A rarefied OTU table from the output files generated in the previous two steps was used for downstream analyses of a-diversity, b-diversity (Lozupone and Knight, 2005) , and phylogenetic trends.
QUANTIFICATION AND STATISTICAL ANALYSIS

RNA-seq Analysis
Mouse RNA-Seq data was aligned to the mm10 assembly of the mouse genome using the STAR aligner 1 . Read counts for genes across all BAM files were computed using the HTSeq software 2 . Differential analysis of RNA-Seq samples utilized the DESeq package for gene expression analysis 3 . False discovery rate correction of P values used for all bioinformatics analyses of this study utilized the Benjamini-Hochberg procedure 4 . Heatmap clustering and production was done using the heatmap function within the NMF package in R 5 . Principal components analysis plots were visualized using the ggbiplot package in R.
STATISTICAL ANALYSIS
Statistical analysis was performed in GraphPad Prism or R software. Results represent mean ± s.e.m. and were analyzed by unpaired Student's t test, Mann-Whitney test, one-way ANOVA, Log-rank (Mantel-Cox) test, as indicated in the figure legends. Given that mouse experiments required littermate controls and complex genotyping, experimental group allocation was not blinded. No relevant exclusion criteria were applied.
DATA AND SOFTWARE AVAILABILITY
RNA seq data have been deposited in GEO repository accession GSE120723.
